Circulating miR‐26a and miR‐21 as biomarkers for glioblastoma multiform
Citations Over TimeTop 19% of 2018 papers
Abstract
Glioblastoma multiform is the most common and lethal primary central nervous system tumor. Circulating microRNAs (miRNAs), present in cell-free bodily fluids, have been gaining importance as cancer biomarkers. The primary aim of this study was to assess whether circulating miRNA-128, -21, and -26a in glioblastoma patients can be used as diagnostic biomarkers. Venous blood samples were collected from 11 noncancerous volunteers and 15 glioblastoma patients pre- and post operation. Also, tissue tumor samples were obtained intra-operationally to assay consistency of miRNA levels in serum and tissue samples. Serum and tissue levels of miRNAs were determined by quantitative reverse transcription PCR. miR-21 and miR-26a were both significantly upregulated in pre- and postoperation serum samples of glioblastoma patients compared with the serum samples of noncancerous controls. We found that all three miR-128, -21, and -26a expression levels were reduced in postoperative serum samples compared with pre-operative serum samples, though this decrease was only significant for miR-26a. The serum miR-26a and miR-21 upregulation in glioblastoma patients compared to noncancerous controls and their downregulation in postoperative serum from glioblastoma patients suggest that these miRNAs could be used as serum-derived miRNA biomarkers for glioblastoma.
Related Papers
- → Enzyme-Instructed Assembly and Disassembly Processes for Targeting Downregulation in Cancer Cells(2017)146 cited
- → Downregulation of miR-140-3p is a Cause of Upregulation of Rhoa Protein in Bronchial Smooth Muscle of Murine Experimental Asthma(2021)7 cited
- → Downregulation of p21/WAF1 Expression by Thymidylate Synthase(2001)17 cited
- → Viral Infection and Abnormal Brain Development: A DNA Microarray Study(2007)1 cited
- → Comparative Transcriptomics of PKD1 Downregulation and PKA Upregulation or Downregulation(2022)